Could Targeting NPM1c+ Misfolding Be a Promising Strategy for Combating Acute Myeloid Leukemia?

Daniele Florio,Daniela Marasco

DOI: https://doi.org/10.3390/ijms25020811

IF: 5.6

2024-01-10

International Journal of Molecular Sciences

Abstract:Acute myeloid leukemia (AML) is a heterogeneous group of diseases classified into various types on the basis of distinct features concerning the morphology, cytochemistry and cytogenesis of leukemic cells. Among the different subtypes, the group "AML with gene mutations" includes the variations of the gene of the multifunctional protein nucleophosmin 1 (NPM1). These mutations are the most frequent (~30–35% of AML adult patients and less in pediatric ones) and occur predominantly in the C-terminal domain (CTD) of NPM1. The most important mutation is the insertion at W288, which determines the frame shift W288Cfs12/Ffs12/Lfs*12 and leads to the addition of 2–12 amino acids, which hamper the correct folding of NPM1. This mutation leads to the loss of the nuclear localization signal (NoLS) and to aberrant cytoplasmic localization, denoted as NPM1c+. Many investigations demonstrated that interfering with the cellular location and oligomerization status of NPM1 can influence its biological functions, including the proper buildup of the nucleolus, and therapeutic strategies have been proposed to target NPM1c+, particularly the use of drugs able to re-direct NPM1 localization. Our studies unveiled a direct link between AML mutations and the neat amyloidogenic character of the CTDs of NPM1c+. Herein, with the aim of exploiting these conformational features, novel therapeutic strategies are proposed that rely on the induction of the selective self-cytotoxicity of leukemic blasts by focusing on agents such as peptides, peptoids or small molecules able to enhance amyloid aggregation and targeting selectively AML–NPM1c+ mutations.

biochemistry & molecular biology,chemistry, multidisciplinary

What problem does this paper attempt to address?

The problem that this paper attempts to solve is the misfolding of proteins and their abnormal intracellular localization caused by NPM1 gene mutations in Acute Myeloid Leukemia (AML). Specifically, the paper explores whether intervening in the misfolding of NPM1c+ (that is, the protein carrying the NPM1 mutation, which is characterized by abnormal cytoplasmic localization) can be an effective strategy for treating AML. The paper points out that the NPM1c+ mutation leads to abnormal aggregation of proteins in the cytoplasm, and this aggregation has obvious amyloid properties. Therefore, a new treatment idea is proposed, that is, by using peptides, peptide analogues or small molecules to enhance the amyloid aggregation of NPM1c+, thereby inducing the selective autotoxicity of leukemia cells to achieve the purpose of treatment.

### Summary of the core issues in the paper:
1. **Biological significance of NPM1c+ mutation**: The NPM1c+ mutation leads to abnormal localization of proteins in the cytoplasm, affecting their normal nucleolar functions, and further affecting the normal physiological processes of cells.
2. **Characteristics of amyloid aggregation**: The NPM1c+ mutant has a significant tendency to amyloid aggregation, and this aggregation may lead to cytotoxicity.
3. **Exploration of treatment strategies**: By enhancing the amyloid aggregation of NPM1c+ and inducing the selective autotoxicity of leukemia cells, it may become a new method for treating AML.

### Key points:
- **NPM1c+ mutation**: The most common mutation type is type A mutation, accounting for 75 - 80% of cases, resulting in misfolding of the C - terminal domain (CTD).
- **Amyloid aggregation**: NPM1c+ mutants form amyloid fibrils in the cytoplasm, and these fibrils are cytotoxic.
- **Treatment potential**: Using specific peptides, peptide analogues or small molecules to promote the amyloid aggregation of NPM1c+ may help to selectively kill leukemia cells.

Through these studies, the paper aims to provide new ideas and potential treatment targets for the treatment of AML.